Literature DB >> 17397042

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection.

Philippe Flandre1, John O'Quigley.   

Abstract

A problem arising in studies on the human immunodeficiency virus (HIV) infection relate to one-sided tests with ordered alternatives as opposed to the more classical two-sided tests. Patients not having a resistance mutation may have a better virologic response to treatment than patients with a single mutation. In turn, those with a single mutation may have a better response to treatment than those patients having two mutations, and so on. In the presence of a continuous outcome, Jonckheere's test for ordered alternatives is well adapted to this situation. Such an analysis does not provide any measure of prediction or explained variation which can complement these results. A measure of strength of effect would be helpful in quantifying the degree of association between the genotypic score (number of mutations) and some continuous virological response. We suggest a simple measure of 'goodness of split' for Jonckheere's test for trend. Interestingly, the measure can be related to the non-parametric measure of association known as gamma. The variance formula for the measure studied here can be seen to differ from the known variance estimate of the gamma measure, and simulations show it to be more accurate. Expectation and variance under H(0) of the measure are provided and a large simulation study is presented. Methods are applied to a recent clinical data set involving HIV-1 infected patients where the number of resistance mutations are investigated as potential predictors of the amount of HIV-1 RNA reduction at week 4. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17397042     DOI: 10.1002/sim.2871

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Authors:  Anne-Geneviève Marcelin; Philippe Flandre; Jean-Michel Molina; Christine Katlama; Patrick Yeni; Francois Raffi; Zeina Antoun; Mounir Ait-Khaled; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

2.  A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation.

Authors:  Purvesh Khatri; Silke Roedder; Naoyuki Kimura; Katrien De Vusser; Alexander A Morgan; Yongquan Gong; Michael P Fischbein; Robert C Robbins; Maarten Naesens; Atul J Butte; Minnie M Sarwal
Journal:  J Exp Med       Date:  2013-10-14       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.